EP1643959A4 - Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment - Google Patents
Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatmentInfo
- Publication number
- EP1643959A4 EP1643959A4 EP04753588A EP04753588A EP1643959A4 EP 1643959 A4 EP1643959 A4 EP 1643959A4 EP 04753588 A EP04753588 A EP 04753588A EP 04753588 A EP04753588 A EP 04753588A EP 1643959 A4 EP1643959 A4 EP 1643959A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mixtures
- methods
- pain treatment
- oligomer conjugates
- calcitonin drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000055006 Calcitonin Human genes 0.000 title 1
- 108060001064 Calcitonin Proteins 0.000 title 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title 1
- 229960004015 calcitonin Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48213003P | 2003-06-24 | 2003-06-24 | |
| PCT/US2004/016784 WO2005004792A2 (en) | 2003-06-24 | 2004-05-27 | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1643959A2 EP1643959A2 (en) | 2006-04-12 |
| EP1643959A4 true EP1643959A4 (en) | 2010-06-09 |
Family
ID=34061937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04753588A Withdrawn EP1643959A4 (en) | 2003-06-24 | 2004-05-27 | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1643959A4 (en) |
| JP (1) | JP4829783B2 (en) |
| WO (1) | WO2005004792A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN03214A (en) | 2011-10-21 | 2015-07-03 | Seachaid Pharmaceuticals Inc | |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098451A1 (en) * | 2001-06-04 | 2002-12-12 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US6495514B1 (en) * | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| KR100345214B1 (en) * | 1999-08-17 | 2002-07-25 | 이강춘 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
-
2004
- 2004-05-27 JP JP2006517158A patent/JP4829783B2/en not_active Expired - Fee Related
- 2004-05-27 WO PCT/US2004/016784 patent/WO2005004792A2/en not_active Ceased
- 2004-05-27 EP EP04753588A patent/EP1643959A4/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098451A1 (en) * | 2001-06-04 | 2002-12-12 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
Non-Patent Citations (3)
| Title |
|---|
| ANTONIO QUATRARO ET AL: "CALCITONIN IN PAINFUL DIABETIC NEUROPATHY", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 339, no. 8795, 1 March 1992 (1992-03-01), pages 746 - 747, XP008073556, ISSN: 0140-6736 * |
| See also references of WO2005004792A2 * |
| SIMANSKI C ET AL: "[Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction]", DER CHIRURG; ZEITSCHRIFT FÜR ALLE GEBIETE DER OPERATIVEN MEDIZEN JUN 1999 LNKD- PUBMED:10427454, vol. 70, no. 6, June 1999 (1999-06-01), pages 674 - 681, XP002578700, ISSN: 0009-4722 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005004792A2 (en) | 2005-01-20 |
| EP1643959A2 (en) | 2006-04-12 |
| JP2007521268A (en) | 2007-08-02 |
| JP4829783B2 (en) | 2011-12-07 |
| WO2005004792A3 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2414670B (en) | Homeopathic formulations useful for treating pain and/or inflammation | |
| IL166780A0 (en) | Use of ikappab-kinase inhibitors in pain therapy | |
| TWI349551B (en) | Thiophenepyrimidinone derivatives and their use in therapy | |
| AU2003293376A8 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
| IL178012A0 (en) | Diphenyl-indol-2-on compounds and their use in the treatment of cancer | |
| IL182652A0 (en) | Nitrobenzindoles and their use in cancer therapy | |
| AU2003298794A8 (en) | Recombinant immunotoxin and use in treating tumors | |
| GB0615918D0 (en) | Composition and its therapeutic use | |
| SG110107A1 (en) | Compound and use in treatment | |
| AU2003250831A8 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
| EP1643959A4 (en) | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment | |
| AU2003245858A8 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
| GB0128431D0 (en) | Improvements in and relating to portable defibrillators | |
| EP1583543A4 (en) | Methods and therapeutic compositions in the treatment of advanced cancer | |
| AU2003209459A8 (en) | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 | |
| IL174968A0 (en) | The use of ifenprodil in the treatment of pain | |
| GB0225688D0 (en) | Therapeutic compounds and their use in therapy | |
| GB0325598D0 (en) | Compound and use in treatment | |
| GB0203042D0 (en) | Anthraquinine compounds their preparation and their use in therapy | |
| GB0203043D0 (en) | Benzimidazloe compounds their preparation and their use in therapy | |
| GB0130733D0 (en) | Therapeutic compounds and their use in therapy | |
| GB0313065D0 (en) | Vaccine and therapeutic treatment | |
| GB0301298D0 (en) | Therapy device and methods of treatment | |
| IL180584A0 (en) | Agents capable of downregulating an msf-a-dependent hif-1alpha and use thereof in cancer treatment | |
| SI1427428T1 (en) | Apoptosis-mimicking natural vesicles and use thereof in medical treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060123 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/00 20060101ALI20060227BHEP Ipc: C07K 7/00 20060101ALI20060227BHEP Ipc: C07K 14/535 20060101ALI20060227BHEP Ipc: C07K 1/113 20060101AFI20060227BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOCON LIMITED |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ODENBAUGH, AMY, L. Inventor name: ANSARI, ASLAM, M. Inventor name: PRICE, CHRISTOPHER, H. Inventor name: EKWURIBE, NNOCHIRI, N. Inventor name: KOSUTIC, GORDANA |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20100512 |
|
| 17Q | First examination report despatched |
Effective date: 20101001 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20151201 |